Skip to main content

L-deprenyl plus l-phenylalanine in the treatment of depression

Summary

The antidepressive efficacy of l-deprenyl (5–10 mg daily) plus l-phenylalanine (250 mg/day) has been evaluated in 155 unipolar depressed patients. Both oral and intravenous administration showed beneficial effects in 90% of outpatients and 80.5% of inpatients. It is concluded that this combined treatment has a potent antidepressive action based on the accumulation of l-phenylethylamine in the brain.

This is a preview of subscription content, access via your institution.

References

  1. Beckmann, H., Strauss, M. A., Ludolph, E.: DL-Phenylalanine in depressed patients: an open study. J. Neural Transm.41, 123–134 (1977).

    Google Scholar 

  2. Bein, H. J.: Rauwolfia and biological psychiatry. TINS5, 37–39 (1982).

    Google Scholar 

  3. Birkmayer, W.: Experimentelle Befunde und neue Aspekte bei extrapyramidalen Erkrankungen. Wien. Zeitschr. f. Nervenheilkunde13, 128–139 (1966).

    Google Scholar 

  4. Birkmayer, W., Neumayer, E., Stöckl, W., Weiler, G.: Defizit essentieller Aminosäuren bei endogener Depression. Wien. klin. Wschr.80, 832–834 (1968).

    Google Scholar 

  5. Birkmayer, W., Neumayer, E., Riederer, P.: Masked depression in old age. In: Masked Depression (Kielbolz, P., ed.) pp. 158–166. Bern-Stuttgart-Wien: H. Huber. 1973.

    Google Scholar 

  6. Birkmayer, W., Riederer, P.: Parkinson's Disease. Wien-New York: Springer. 1983.

    Google Scholar 

  7. Blackwell, B.: Hypertensive crises due to monoamine oxidase inhibitors. Lancetii, 849–851 (1963).

    Google Scholar 

  8. Boulton, A., Milward, L.: Separation, detection and quantitative analysis of urinary beta-phenylethylamine. J. Chromatogr.57, 287–296 (1971).

    Google Scholar 

  9. Caroll, B. J.: Monoamine precursors in the treatment of depression. Clin. Pharm. Ther.12, 743–761 (1971).

    Google Scholar 

  10. Elsworth, J. D., Glover, V., Reynolds, G. P., Sandler, M., Lee, A. L., Phaupradit, P., Shaw, K. M., Stern, G. M., Kumar, P.: Deprenyl administration in man. Selective monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacol.57, 33–38 (1978).

    Google Scholar 

  11. Fischer, E., Spatz, H., Heller, B., Reggiani, H.: Phenylethylamine content of human urine and rat brain, its alteration in pathological conditions and after drug administration. Experientia28, 307 (1972).

    Google Scholar 

  12. Fischer, E., Heller, B., Nachon, M., Spatz, H.: Therapy of depression by phenylalanine. Arzneimittel-Forsch. (Drug Res.)25, 132 (1975).

    Google Scholar 

  13. Glover, V., Sandler, M., Owen, F., Riley, G. J.: Dopamine is a monoamine oxidase-B substrate in man. Nature (Lond.)265, 80–81 (1977).

    Google Scholar 

  14. Hamilton, M.: A rating scale for depression. J. Neurol. Neurosurg. Psychiat.23, 56–61 (1960).

    Google Scholar 

  15. Inwang, E. E., Mosnaim, A. D., Sabelli, H. C.: Isolation and characterization of phenylethylamine and phenylethanolamine from human brain. J. Neurochem.20, 1469–1473 (1973).

    Google Scholar 

  16. Knoll, J., Ecsery, Z., Nievel, J., Knoll, B.: Phenylisopropyl-methylpropinylamin HCI. E-250 egy új hatásspektrumu pszichoenergetikum. MTA V. Oszt. Közl.15, 231 (1964).

    Google Scholar 

  17. Knoll, J., Magyar, K.: Some puzzling effects of monoamine oxidase inhibitors. In: Monoamine Oxidase — New Vistas (Advances in Biochemical Psychopharmacology, Vol. 5) (Costa, E., Sandler, M., eds.), pp. 393–408. New York: Raven Press. 1972.

    Google Scholar 

  18. Knoll, J.: Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In: Monoamine Oxidase and Its Inhibition (Ciba Foundation Symposium 39, new series), pp. 135–161. Amsterdam-Oxford-New York: Elsevier-Excerpta Medica-North-Holland. 1976.

    Google Scholar 

  19. Mann, J., Gershon, S.: Deprenyl, a selective monoamine oxidase type B inhibitor in endogenous depression. Life Sci.26, 877–882 (1980).

    Google Scholar 

  20. Mendis, N., Pare, C. M. B., Sandler, M., Glover, V., Stern, G.: (-)Deprenyl in treatment of depression. In: Monoamine Oxidase Inhibitors — The State of the Art (Youdim, M. B. H., Paykel, E. S., eds.), pp. 171–176. Chichester: Wiley. 1981.

    Google Scholar 

  21. Mendlewicz, J., Youdim, M. B. H.: Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO type B inhibitor. J. Neural Transm.43, 279–286 (1978).

    Google Scholar 

  22. Mendlewicz, J., Youdim, M. B. H.: L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation. Brit. J. Psychiat.142, 508–511 (1983).

    Google Scholar 

  23. Reynolds, G. P., Riederer, P., Sandler, M., Jellinger, K., Seemann, D.: Amphetamine and 2-phenylethylamine in post-mortem parkinsonian brain after (-)deprenyl administration. J. Neural Transm.43, 271–277 (1978).

    Google Scholar 

  24. Varga, E., Tringer, L.: Clinical trial of a new type promptly acting psychoenergetic agent (phenylisopropylmethylpropinyl-HCl. E-250). Acta Med. Acad. Sci. Hung.23, 289–295 (1967).

    Google Scholar 

  25. Yang, H.-Y. T., Neff, N. H.: ß-Phenylethylamine: a specific substrate for type B monoamine oxidase of brain. J. Pharmacol. Exp. Ther.187, 365–371 (1973).

    Google Scholar 

  26. Youdim, M. B. H., Finberg, J. P. M.: Monoamine oxidase inhibitor antidepressants. In: Psychopharmacology 1 (Grahame-Smith, D. G., ed.), pp. 39–70. Amsterdam-Oxford-Princeton: Excerpta Medica. 1983.

    Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Birkmayer, W., Riederer, P., Linauer, W. et al. L-deprenyl plus l-phenylalanine in the treatment of depression. J. Neural Transmission 59, 81–87 (1984). https://doi.org/10.1007/BF01249880

Download citation

Key words

  • Depression syndrome
  • deprenyl
  • phenylalanine
  • antidepressants